As of July 29, 2026, SymBio Pharmaceutical transferred 28,540 shares through the exercise of stock acquisition rights, bringing the total issued shares to approximately 76,434,210.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4582","jir_company_name":"SymBio Pharmaceutical Limited","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-07-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4582-20260730-01.pdf","jir_short_summary":"As of July 29, 2026, SymBio Pharmaceutical transferred 28,540 shares through the exercise of stock acquisition rights, bringing the total issued shares to approximately 76,434,210.","jir_summary":"### Overview of Exercise Status\nSymBio Pharmaceutical announced the exercise status of the 66th stock acquisition rights issued in August 2025. Between July 1 and 29, 2026, 37,940 stock acquisition rights were exercised, and 28,540 new shares were transferred. As a result, the remaining unexercised stock acquisition rights totaled 120,510 units. The exercise rate was 19.0%, and unexercised rights continue to exist.\n\n### Impact on Shareholders and Future Outlook\nAlthough the total issued shares increased due to the exercise of the stock acquisition rights, the dilution of shares is considered limited. While ongoing monitoring of the exercise status is necessary, no significant impact on business performance has been observed at this time. Continued attention to exercise trends and capital policy developments is required in the future.","jir_financial_highlights":"Total Issued Shares: 76,434,210 shares (Unknown)\nShares Delivered Since the Beginning of the Month: 3,794,000 shares (Unknown)\nNumber of Stock Acquisition Rights Exercised Since the Beginning of the Month: 37,940 units (Unknown)","jir_category":"","jir_hashtags":"#SymBioPharmaceutical, #IRRelated, #JapanStocks","jir_key_figures":"Total Issued Shares: 76,434,210 shares\nShares Delivered Since the Beginning of the Month: 3,794,000 shares\nNumber of Stock Acquisition Rights Exercised Since the Beginning of the Month: 37,940 units","jir_meta_title":"\u3010SymBio Pharmaceutical\u3011Stock Acquisition Rights Exercise Status\uff5cJuly 2026","jir_meta_description":"As of July 29, 2026, SymBio Pharmaceutical transferred 28,540 shares through the exercise of stock acquisition rights. Total issued shares are approximately 76,434,210. Details explained.","jir_og_title":"\u3010SymBio Pharmaceutical\u3011Stock Acquisition Rights Exercise Status\uff5cJuly 2026","jir_og_description":"Overview of SymBio Pharmaceutical's stock acquisition rights exercise status and changes in share count. Providing important information for investors.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60013,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-89910","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n